Introduction {#sec1-1}
============

The 2009 influenza pandemic had highlighted the need for more global data on severe influenza disease, so the WHO recommended conducting surveillance for hospitalized severe acute respiratory infection (SARI), as well as influenza-like illness (ILI) in outpatients \[[@ref1]\]. SARI surveillances are now conducted in many countries around the world; however, because of limited resources, they are only conducted in limited settings in the Middle East and Egypt \[[@ref5]\].

Despite that the roles of different respiratory viruses in the etiology of SARI are becoming clear \[[@ref8]\], the presence of a virus does not imply either a more benign clinical course or that systemic inflammatory responses or complications will not happen \[[@ref9]\]. Moreover, the true impact of viral infections in the etiology of SARIs requiring hospitalization and intensive care unit (ICU) admission is still unknown \[[@ref10]\]. Obtaining accurate information on the epidemiology of critically ill SARI patients and how they are managed should help intensive care practitioners to understand the factors associated with progression from acute respiratory infection to more severe critical illness \[[@ref7],[@ref9],[@ref10]\].

In our previous work \[[@ref11]\], we had addressed the clinical characteristics and outcomes of Egyptian adult and pediatric patients with SARI prospectively enrolled at Cairo University Hospitals (CUH) from 2010 to 2014. In the current study, we analyze data of those SARI patients admitted to the ICU. We aimed to investigate the role of different respiratory viruses in causing critical illness requiring ICU admission, which pathogens were related to severe outcomes, and to address the impacts of SARI on the clinical outcomes of patients admitted to the ICU, in terms of morbidity and mortality.

Methods {#sec1-2}
=======

Study population {#sec2-1}
----------------

Cairo University Hospital (CUH) is a 5100-beds tertiary referral teaching hospital. Hospitalized adults (defined as age ≥18 years old), as well as pediatric patients (age \<18 years old), who were admitted into CUH with the diagnosis of SARI and provided a respiratory sample, from February 2010 to February 2014, were prospectively enrolled. Due to an annual review by dedicated investigators and updates to WHO guidelines, the case definition for SARI had evolved over the study period. Before February 2010, as a global-surveillance case definition of SARI did not exist, the definition for SARI was adapted from the WHO protocol on the rapid response for persons ≥5 years old \[[@ref1]\], whereas, for children \<5 years old, SARI definition was adapted from the program for Integrated Management of Childhood Illness \[[@ref2]\]. After March 2011, the global standards and tools for influenza surveillance developed by the WHO were adopted \[[@ref3]\]. As of January 2014, the WHO surveillance case definition for SARI was implemented \[[@ref4]\] as follows, acute respiratory infection with history of fever or measured fever of ≥38°C, and cough, with onset within the last 10 days, and requiring hospitalization \[[@ref4]\]. An enrollment form was used to collect data from enrolled eligible patients including patient demographics, medical history, clinical signs and symptoms, the indication for ICU admission, comorbidities, reported influenza vaccine status, recent travel history, treatment, clinical course, the method and indication of respiratory support, complications, and outcome. Patients with incomplete medical records were excluded. Associated comorbidities (if any) were evaluated using the Charlson Age-Comorbidity Index (CACI) \[[@ref12]\]. For comparative purposes, and according to whether the patients were admitted to the ICU or not, they were divided into 2 groups; those admitted to the ICU (SARI-ICU) and those not admitted (SARI non-ICU).

Clinical samples and viral detection techniques {#sec2-2}
-----------------------------------------------

Nasopharyngeal (NP) and oropharyngeal (OP) swabs for detecting viruses and blood cultures for detecting bacteria were taken from eligible patients on admission using operating procedures described by the WHO \[[@ref13]\]. Specimens were taken an average of 7 days after illness onset (range: 1--66 days).

Total nucleic acid (TNA) was extracted by the automated KingFisher Flex Magnetic Particle Processor (Thermo Scientific, Waltham, MA, USA) using MagMAX Total Nucleic Acid Isolation Kit (Cat No. AM 1840, Applied Biosystems, Foster, CA, USA) according to the manufacturer's instructions. The viral target was amplified using specific primers and probes produced by the CDC (Atlanta, GA, USA) and following standard protocol for reverse transcription polymerase chain reaction detection. From 2010 to 2012, testing for RSV, adenovirus, human parainfluenza viruses (hPIV) 1, 2 and 3, influenza (A and B) and human metapneumovirus was conducted at CUH laboratory and sent for confirmation by the Naval Medical Research Unit No.3 (NAMRU-3) laboratory. From 2013 to 2014, testing was conducted at CUH laboratory. For all samples, the human RNase P gene (RP) was tested as an internal positive control to ensure proper sample collection and nucleic acid extraction. Samples were considered positive to the viral target if the amplification curve crossed the threshold line before cycle 40. All clinical samples should be positive to RP with cutoff value ≤37, as prescribed previously \[[@ref7]\]. Blood samples were collected for detection of Mycoplasma pneumonia, Chlamydia pneumonia, and Legionella pneumophila, using RT-qPCR.

Ethical standards {#sec2-3}
-----------------

Prior to study initiation, the study protocol was reviewed and approved by Institutional Review Board at the NAMRU-3, as well as the ethical committee of CUH, in compliance with all applicable federal U.S. regulations governing the protection of human subjects. Informed written consent was obtained from the patients or patients' parent/legal guardian (in case of pediatric patients).

Statistical analysis {#sec2-4}
--------------------

Data analyses were conducted using the software SPSS (Statistical Package for the Social Science; IBM Corp., NY, USA); ver. 22. Data were summarized using median (range) for quantitative variables and number and percent for qualitative variables. Comparison between groups was done using the Chi-square test for qualitative variables, independent sample *t*-test for normally distributed quantitative variables, while the Mann-Whitney U test was used for quantitative variables that are not normally distributed. Indicators of severe disease were assessed for each pathogen of interest using Mantel-Haenszel estimates to calculate odds ratios and confidence intervals and the Mantel-Haenszel chisquared test to assess statistical significance \[[@ref14]\]. Logistic regression was used to examine associations between viral respiratory pathogens and severe outcomes, defined as illness requiring ventilation or resulting in death while controlling for demographic and clinical characteristics. All tests were two-sided, and differences with *p*\<0.05 were considered significant.

Results {#sec1-3}
=======

Demographic data of the study population {#sec2-5}
----------------------------------------

Out of 3,207 participants enrolled in this SARI surveillance, 1,075 (33.5%) had positive results for one or more tested viruses. Out of those 1,075 patients, 219 (20.3%) were admitted to the ICU (SARI-ICU group). They included 116 (53%) females and 103(47%) males. The median age was 3 years (range 0-85 years). Children less than 18 years had a significantly higher viral etiology (157 patients, 72%) compared to that in adults (62, 28%); *p*=0.000. The highest rates of viral infections were reported for RSV (82/219, 37%), multiple viruses (41/219, 19%), influenza (36/219, 16%), and adenovirus (22/219, 10%), respectively. [Figure 1](#fig001){ref-type="fig"} shows these details. Reasons for ICU admission were: lower respiratory tract infection; LRTI (63/219, 29%), severe wheezing with respiratory distress (27/219, 12%), and respiratory failure that required respiratory support (129, 59%). One hundred patients (45%) needed mechanical ventilation (MV), either non-invasive (n=23) or invasive (n=77). Indications for non-invasive MV were acute nonhypercapnic respiratory failure due to pneumonia in 5 patients, respiratory failure due to cardiogenic pulmonary oedema (3 patients), acute hypercapnic respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in 8 patients, and acute severe asthma (7 patients). Indications for invasive MV were: acute respiratory distress syndrome (ARDS) 15 patients, acute or acute-on chronic respiratory failure due to neuromuscular disorders (24 patients), the presence of contraindication(s) to NIV (22 patients), and no response to initial NIV (16 patients). The smoking rate was significantly higher in ICU than non-ICU patients (12% *vs* 3%, *p*=0.034) ([Table 1](#table001){ref-type="table"}).

Clinical and radiological characteristics in SARI-ICU *vs* non-ICU patients {#sec2-6}
---------------------------------------------------------------------------

In comparison to non-ICU SARI patients (856/1,057, 79.7%), SARI-ICU ones had significantly less predominant signs and symptoms at presentation. Particularly, they had less viral prodromal symptoms, as well as, wheezes, nasal congestion, and sputum production (*p*=0.000 each). ICU pediatric patients had significantly higher viral load than adults (*p*=0.000), which was also observed among individual viral pathogens (except for PIV). SARI-ICU patients with influenza had significant signs and symptoms at presentation in comparison to non-influenza ones, followed by those with RSV and multiple viral infections, in comparison to non-RSV, and single viral infections, respectively. Patients whose specimens were collected within 5 days of the onset of symptoms were more likely to have a viral pathogen detected than those whose specimens were collected later (78% *versus* 32%, *p*=0.002).

With regards to radiologic features, there were no significant differences between ICU and non-ICU patients, respectively. Only patients with influenza had more significant radiologic abnormalities than non-influenza ones (*p*=0.017).

Patients with comorbidities (n=134, 61%) were significantly older compared to those with no comorbidities (median age: 59 *versus* 3, *p*=0.000). Additionally, they were significantly more likely to be symptomatic. The majority (86%) of SARI-ICU patients had Charlson Age-Comorbidity Index (CACI) scores ≤3 ([Table 2](#table002){ref-type="table"}).

Among individual viral pathogens, SARI-ICU patients with influenza virus had significantly different chronic respiratory (78% *vs* 22%, *p*=0.006), cardiac (33% *vs* 67%, *p*=0.046), and endocrine (31% *vs* 69%, *p*= 0.023) disorders than those with non-influenza SARI-ICU viral infections, respectively. For influenza vaccination history, 177/219 (81%) cases did not receive the vaccine within the 12 months prior to hospital admission, while 42/219 (19%) were reported as unknown for an influenza vaccination status. [Table 1](#table001){ref-type="table"} details these results.

Clinical course, complications, and outcomes in SARIICU patients {#sec2-7}
----------------------------------------------------------------

In comparison to non-ICU patients, SARI-ICU ones had significantly longer hospital stay (5 days, range 1-96, mean ± SD 6.31±7.91 *versus* 1 day, range 1-70, mean ± SD 3.05±8.59; 95% confidence interval 5.84-16.79; *p*=0.000). Also, ICU patients had significantly higher rates of pneumonia (7% *vs* 2%, *p*=0.022) than the non-ICU ones. With regards to complications, ICU patients had significantly higher rates of developing respiratory failure and ARDS (9% *vs* 0% and 6% *vs* 0%, *p*=0.000), respectively. For individual viral pathogens, RSV-ICU patients had significantly lower rates of pneumonia, respiratory failure, and ARDS, than those with non-RSV (16% *vs* 84%, 22% *vs* 78%, and 10% *vs* 90%, *p*=0.000), as well as shorter hospital stay (median 1 day, range 1-70, mean ± SD 3.93±7.73 *versus* 4 days, range 1-88, mean ± SD 5.40±8.97; 95% confidence interval 3.46 -- 14.39; *p*=0.000).

Overall mortality in SARI-ICU patients was 24/219 (11%), peaked at 1% in 2014, and was significantly higher than in those with non-ICU (0%), *p*=0.000. Overall, only 2(8%) were adults, while 22 (92%) were children. Among children, 18(75%) were aged \<5 years. Overall, two-thirds (16/24) had comorbidities. All patients who died were mechanically ventilated. Notably, all patients who died tested positive for a viral pathogen; twelve (50%) were positive for RSV, four (17%) for influenza virus, two for adenovirus, one for hMPV, one for PIV and four (17%) for mixed viral infections, respectively. Among individual viral pathogens, SARI-ICU patients with multiple viral infections had significantly lower death incidence (10% *vs* 90%, *p*=0.045) than those with single infection ([Table 1](#table001){ref-type="table"}).

Severe outcomes in SARI-ICU patients {#sec2-8}
------------------------------------

In comparison to non-ICU patients, the ICU ones had significantly severe outcomes, as indicated by illness requiring mechanical ventilation and/or resulting in death (OR 3.840, 95% CI 0.148-14.987, *p*=0.000, and OR 1.823, 95% CI 0.585-4.070, *p*=0.000, respectively). For individual viral pathogens, no infections were independently associated with increased severity of illness in comparison to those not infected with each of these pathogens. When analyses were stratified by age, ICU patients \<18 years of age were more likely than those non-ICU ones to experience a severe outcome (OR 3.437, 95% CI 0.348-7.987, *p*=0.000 and OR 1.113, 95% CI 0.335-3.170, *p*=0.002, respectively). Among ICU patients \>18 years of age, there was no significant difference between ICU and non-ICU patients for severe outcomes, and only those adults with influenza were more likely to experience a severe outcome than those with non-influenza (OR 3.551, 95% CI 1.148-10.987, *p*=0.028). [Table 3](#table003){ref-type="table"} shows these details (Data for PIV, hMPV, Bocavirus, rhino-, and enterovirus are not shown in the table).

![Flow chart of the study subjects.](mrm-15-1-465-g001){#fig001}

Logistic regression analysis for severe outcomes {#sec2-9}
------------------------------------------------

Logistic regression analysis was used to further examine associations with severe outcomes in SARI-ICU patients with complete demographic data and clinical risk factors. By univariate analysis, individuals with multiple viral infections, CACI score ≥3, radiological abnormalities, and longer hospital stay were more likely to experience a severe outcome than those with single viral infection (OR 4.362, 95% CI 1.384-13.754, *p*=0.012), CACI score \<3 (OR 9.328, 95% CI 1.860-25.921, *p*=0.020), no radiological abnormalities (OR 10.779, 95% CI 2.195-52.945, *p*=0.003), and shorter hospital stay (OR 3.035, 95% CI 1.005-9.067, *p*=0.024), respectively. Multivariate analysis confirmed these results where individuals with CACI score ≥3, radiological abnormalities, and longer hospital stay were more likely to experience a severe outcome than those with CACI score \<3 (OR 7.323, 95% CI 1.226-23.022, *p*=0.001), no radiological abnormalities (OR 3.339, 95% CI 1.183-9.422, *p*=0.023), and shorter hospital stay (OR 4.035, 95% CI 1.011-11.060, *p*=0.005), respectively ([Table 4](#table004){ref-type="table"}).

###### 

Demographic, clinical, and radiological characteristics of ICU and non-ICU SARI cases in Egypt, 2010-2014.

  Characteristic                       Non-ICU SARI (n=856) (%)   ICU SARI (n=219) (%)   p^[\*](#tfn1){ref-type="table-fn"}^   RSV- ICU (n=82) (%)   p^\$^   Multiple viruses-ICU (n=41) (%)   p^\$^   PIV-ICU (n=20) (%)   p^\$^   Adeno- virus-ICU (n=22) (%)   p^\$^   Influenza viruses-ICU (n=36) (%)   p^\$^
  ------------------------------------ -------------------------- ---------------------- ------------------------------------- --------------------- ------- --------------------------------- ------- -------------------- ------- ----------------------------- ------- ---------------------------------- -------
  Demographics Gender                                                                                                                                                                                                                                                                                        
  Female                               453/856(53)                116/219(53)            0.94                                  40(49)                0.338   16(39)                            0.048   9(45)                0.456   11(50)                        0.824   20(56)                             0.855
  Male                                 403/856(47)                103/219(47)                                                  42(51)                        25(61)                                    11(55)                       11(50)                                16(44)                             
  Age in years                                                                                                                                                                                                                                                                                               
  Median                               0.83                       3.00                                                         0.67                          1.00                                      1.00                         1.00                                  5.00                               
  (Range)                              0-74                       0-85                                                         (0-85)                        (0-77)                                    (0-74)                       (0-57)                                (0-76)                             
  \<18 years                           824/856(96)                157/219(72)            0.000                                 68(83)                0.006   32(78)                            0.029   13(65)               0.603   11(50)                        0.017   10(28)                             0.000
  \>18 years                           32/856(4)                  62/219(28)                                                   14(17)                        9 (22 )                                   7(35)                        11(50)                                26(72)                             
  Signs and symptoms at presentation                                                                                                                                                                                                                                                                         
  Shortness of breath                  856/856(1)                 219/219(1)             NA                                    82(100)               NA      41(100)                           NA      20(100)              NA      22(100)                       NA      36(100)                            NA
  Sore throat                          231/856(27)                42/219(19)             0.024                                 9(11)                 0.080   7(17)                             0.706   7(35)                0.074   6(27)                         0.311   8(22)                              0.614
  Sputum production                    508/856(59)                85/219(39)             0.000                                 29(35)                0.243   15(36)                            0.601   10(50)               0.374   9(41)                         0.978   22(61)                             0.009
  Body aches                           140/856(16)                25/219(11)             0.375                                 14(17)                0.035   3(21)                             0.002   7(35)                0.457   2(9)                          0.031   22(61)                             0.000
  Tachypnea                            788/856(92)                212/219(97)            0.002                                 81(99)                0.405   41(100)                           0.280   19(95)               0.000   22(100)                       0.000   34(94)                             0.000
  Nasal congestion                     577/856(67)                70/219(32)             0.000                                 48(59)                0.001   25(61)                            0.013   19(95)               0.000   20(91)                        0.011   30(83)                             0.014
  Wheezing                             732/856(86)                149/219(68)            0.000                                 55(67)                0.031   31(76)                            0.171   15(75)               0.571   22(100)                       0.002   26(72)                             0.022
  Stridor                              4/856 (0)                  3/219(1)               0.119                                 5(6)                  0.024   0 (0)                             0.001   1(5)                 0.944   0 (0)                         0.034   18(50)                             0.000
  Abnormal breath sounds               430/856(50)                128/219(58)            0.053                                 30(37)                0.001   18(44)                            0.199   12(60)               0.640   17(77)                        0.016   26(72)                             0.017
  Nausea or vomiting                   105/856(12)                11/219(5)              0.011                                 9(11)                 0.022   2(5)                              0.002   4(20)                0.471   4(18)                         0.097   18(50)                             0.000
  Convulsions                          92/856(11)                 16/219(7)              0.184                                 6(7)                  0.034   3(7)                              0.007   3(15)                0.499   2(9)                          0.032   19(53)                             0.000
  Smoking (age ≥12 yrs)                26/856(3)                  26/219(12)             0.034                                 6(7)                  0.375   6(14)                             0.604   3(15)                0.466   2(9)                          0.878   9(25)                              0.007
  Pregnancy                            8/856(1)                   3/219(1)               0.974                                 0 (0)                 0.370   0 (0)                             0.062   1(5)                 0.366   0 (0)                         0.838   2(6)                               0.924
  Radiological findings                                                                                                                                                                                                                                                                                      
  CXR abnormalities                    180/856(21)                37/219(17)             0.088                                 12(15)                0.912   6(14)                             0.923   3(15)                0.910   6(27)                         0.211   10(28)                             0.017
  CXR infilterates                     319/856(37)                74/219(34)             0.117                                 29(35)                0.398   15(36)                            0.797   8(40)                0.875   10(45)                        0.473   12(33)                             0.500
  Clinical course                                                                                                                                                                                                                                                                                            
  Pneumonia                            13/856(2)                  16/219(7)              0.022                                 13(16)                0.000   4(10)                             0.515   1(5)                 0.048   4(18)                         0.879   3(8)                               0.114
  Mechanical ventilation               0/856 (0)                  00/219(46)             0.000                                 43(52)                0.071   13(32)                            0.047   8(40)                0.644   7(32)                         0.000   17(47)                             0.000
  Complications                                                                                                                                                                                                                                                                                              
  Respiratory failure                  2/856 (0)                  22/21 9(10)            0.000                                 18(22)                0.000   4(10)                             0.452   2(10)                0.702   4(18)                         0.118   1(3)                               0.417
  ARDS                                 2/856 (0)                  15/219(7)              0.000                                 8(10)                 0.070   4(10)                             0.752   0 (0)                0.842   0 (0)                         0.175   0 (0)                              0.699
  Outcomes^\$^                                                                                                                                                                                                                                                                                               
  Discharged                           833/856(97)                123/219(56)            0.000                                 30(36)                0.388   17(41)                            0.033   12(60)               0.373   17(77)                        0.767   22(61)                             0.975
  Transferred                          23/856(3)                  72/219(33)                                                   40(49)                        20(49)                                    7(35)                        3(14)                                 10(28)                             
  Died                                 0/856 (0)                  24/219(11)                                                   12(15)                        4(10)                                     1(5)                         2(9)                                  4(11)                              

^\*^Comparison between SARI-ICU and non-ICU SARI patients; \$SARI-ICU patients with a positive result for that pathogen compared to a reference group of tested SARI-ICU patients with a negative result; RSV, respiratory syncytial virus; PIV, para-influenza virus; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; NA, not available.

Discussion {#sec1-4}
==========

We have recently published the largest surveillance Egyptian study that addressed the epidemiological patterns of SARI due to viruses in both children and adult population and their relation to the clinical characteristics and outcomes of those patients \[[@ref11]\]. Despite that viral pathogens were encountered in one-third of SARI patients, these infections had no negative impacts on clinical features, clinical course, and outcomes of those patients \[[@ref11]\]. In this related study, we aimed to address the impacts of SARI on the clinical outcomes of patients admitted to the ICU, in terms of morbidity and mortality. Few studies had shed light on SARI patients admitted to the ICU \[[@ref9],[@ref10],[@ref14]\].

One-fifth of our SARI cohort needed ICU admission, the majority of whom (72%) were children, with the highest prevalence for RSV, influenza, adenovirus, and multiple viruses (37%, 16%,10%, and 19%), respectively. Forty-seven percent of SARI patients with influenza were candidates for ICU admission. These results are in accordance with those reported at different parts of the world among different SARI populations \[[@ref6],[@ref7],[@ref9],[@ref10],[@ref14]\]. Among influenza-positive SARI patients, Meerhoff *et al.* \[[@ref15]\] identified age \>15 years, those having lung, heart, kidney or liver disease or being pregnant, as risk factors for ICU admission and/or fatal outcome.

Despite that 20% of our SARI patients needed ICU admission, 81% of our cohort did not receive the influenza vaccine within the 12 months prior to hospital admission. This should alert the healthcare leaders in our locality for implementing effective vaccination strategies for populations at risk for influenza.

In the current study, it seems that neither clinical signs and symptoms at presentation nor radiologic findings did help the clinician stratifying SARI patients into high-risk groups with more severe disease and/or in need for ICU admission. These data are in agreement with those reported by Wansaula and coworkers \[[@ref17]\], which may represent a challenge to the clinicians. On the other hand, the relatively low number of SARI-ICU patients in the current study may explain this lack of association between clinical and/or radiological features and severity of the disease.

One might expect that the presence of medical comorbidities will put SARI patients into higher risk for severe disease and ICU admission. In this respect, it was also disappointing and contradicting other studies \[[@ref11],[@ref15],[@ref17]\], as it was observed that- in terms of comorbidities- there were no significant differences between ICU and non-ICU SARI patients. Definitely, studies with larger numbers of patients are needed to clarify these associations. SARI-ICU patients with influenza virus had significantly higher chronic respiratory, yet lower cardiac and endocrine disorders than those with non-influenza patients, respectively. These results support those reported by different worldwide studies \[[@ref15],[@ref17]\] and highlight the importance of screening patients with those comorbidities for influenza viruses and meticulous observation for influenza-related complications and outcomes. In a study from South Africa, Cohen *et al.* \[[@ref19]\] enrolled 1,376 patients with influenza-associated SARI and on multivariable analysis, they found that underlying medical conditions other than HIV were one of the important factors associated with death (OR 2.9, 95%CI 1.2.7.3, *p*=0.021).

###### 

Charlson Age-Comorbidity Index (CACI) scores among SARI-ICU patients (n=219).

             Number (%)   *p*
  ---------- ------------ -------
  CACI ≤3    188(86)      0.002
  CACI \>3   31(14)       

###### 

Indicators of the severity of SARI-ICU patients by pathogen and age.

                         SARI-ICU cases\$   RSV              Adenovirus   Influenza   Multiple viruses                                                                                                       
  ---------------------- ------------------ ---------------- ------------ ----------- ------------------ ------- -------- --------------- ------- -------- ---------------- ------- -------- --------------- -------
  All participants                                                                                                                                                                                           
  Ventilation            100/219            3.84             0.000        43/82       0.474              0.123   7/22     1.486           0.380   17/36    1.078            0.837   13/41    0.486           0.069
                         \(46\)             (0.148-14.987)                \(52\)      (0.281-1.161)              \(32\)   (0.613-3.601)           \(47\)   (0.527-2.206)            \(32\)   (0.236-0.998)    
  Death                  24/219             1.823            0.000        12/82       1.194              0.388   2/22     0.795           0.768   4/36     1.019            0.974   4/41     0.854           0.785
                         \(11\)             (0.585-4.070)                 \(15\)      (0.378-5.167)              \(9\)    (0.174-3.636)           \(11\)   (0.326-3.180)            \(10\)   (0.275-2.648)   
  Children \< 18 years                                                                                                                                                                                       
  Ventilation            81/157             3.437            0.000        36/68       1.100              0.768   7/11     1.703           0.412   5/10     0.934            0.917   13/32    0.574           0.167
                         \(52\)             (0.348-7.987)                 \(53\)      (0.585-2.070)              \(64\)   (0.478-6.067)           \(50\)   (0.259-3.364)            \(40\)   (0.261-1.262)   
  Death                  22/157             1.113            0.002        12/68       1.693              0.255   2/11     1.400           0.681   2/10     1.588            0.576   4/32     0.849           0.783
                         \(14\)             (0.335-3.170)                 \(18\)      (0.684-4.190)              \(18\)   (0.282-6.956)           \(20\)   (0.314-8.019)            \(13\)   (0.266-2.710)    
  Adults \>18 years                                                                                                                                                                                          
  Ventilation            19/62              0.283            0.170        4/14        2.961              0.053   3/11     2.202           0.247   12/26    3.551            0.028   0/9      0.791           0.080
                         \(31\)             0.189-0.424)                  \(29\)      (0.741-5.927)              \(27\)   (0.579-8.383)           \(46\)   (1.148-10.987)           \(0\)    (0.678-3.922)   
  Death                  2/62               \--              \--          0/14        0.660              0.719   0/11     0.817           0.786   2/26     0.400            0.339   0/9      0.850           0.671
                         \(3\)                                            \(0\)       (0.461-3.261)              \(0\)    (0.724-0.921)           \(8\)    (0.293-0.545)            \(0\)    (0.764-0.945)   

^\*^Comparison between SARI-ICU and non-ICU SARI patients; \$SARI-ICU patients with a positive result for that pathogen compared to a reference group of tested SARI-ICU patients with a negative result; RSV, respiratory syncytial virus; ICU, intensive care unit. Severe outcome is defined as illness requiring ventilation or resulting in death.

Comparing the clinical course, complications, and outcomes between SARI-ICU and non-ICU patients revealed interesting results. SARI-ICU patients had significantly higher rates of hospital stay, pneumonia, respiratory failure and ARDS, and mortality.

Previous studies showed conflicting results on the impacts of viral infections on clinical outcomes in both patients with SARI \[[@ref7],[@ref9],[@ref11],[@ref15],[@ref17]\] and those with SARI-ICU \[[@ref7],[@ref9],[@ref10],[@ref15],[@ref16],[@ref19]\]. Differences in patients' numbers, enrollment criteria, and laboratory methodologies could explain these results. Moreover, our results confirm that although PCR has been established as a reliable diagnostic assay with high sensitivity and specificity for respiratory viruses, particularly for RSV \[[@ref20]\], the clinical implications of such positive laboratory results are still less clear \[[@ref14]\].

Our data showed a mortality rate of 11%, the majority of which (92%) was reported among children, 75% of the later were aged \<5 years. Notably, all patients who died tested positive for a viral pathogen, 50% were positive for RSV. Our findings may contradict those observed by Sakr and colleagues \[[@ref10]\], who reported ICU and in-hospital mortality rates of 20.2 and 27.2 %, in 663 SARI patients, respectively. Despite that the authors reported a viral etiology of only 7.7% in their SARI patients, organ failure occurred in 74.7 % of patients in the ICU, and this could explain these high mortality rates. Our mortality data underscore those in previous reports denoting that RSV is a well-established respiratory virus known to cause severe disease by itself, especially in younger children \[[@ref6],[@ref11],[@ref16],[@ref21]\].

Data analysis of severe outcomes among our SARI-ICU patients appears to be interesting. SARI-ICU patients had significantly severe outcomes, in comparison to those non-ICU ones, in terms of illness requiring mechanical ventilation and/or resulting in death, which remained significant among children but not adults (except for those with influenza). Multivariate logistic regression analysis revealed that higher Charlson Age-Comorbidity Index scores, radiological abnormalities, and longer hospital stay are risk factors for severe outcomes among SARI-ICU patients. Sakr *et al.* \[[@ref10]\] observed that organ failure occurred in 74.7% of SARI patients in the ICU, and it was mostly respiratory (53.8%), cardiovascular (44.5%), and renal (44.6%), respectively. Adding to the dilemma of our findings, it seems logical that SARI-ICU patients with respiratory comorbidities and longer hospital stay are more vulnerable to severe outcomes, yet no individual viral pathogen was associated with severe outcomes of those patients.

Despite that, our data for severe outcomes could be counterintuitive, as various studies have indicated that higher viral loads among SARI patients are related to more severe disease and locally increased cytokine production \[[@ref6],[@ref9],[@ref17],[@ref22]\]. However, other studies failed to replicate this finding \[[@ref11],[@ref14],[@ref16],[@ref25],[@ref26]\]. Our findings may have been influenced by the selection of hospitalized and seriously ill patients and/or the use of PCR for assessment of the viral load. Moreover, viral load may be one of many factors that could be related to disease severity. In this regards the role of a deleterious or counter-productive immune response may be another factor related to disease severity, which has been the subject of several studies \[[@ref27],[@ref28]\].

###### 

Logistic regression for predictors of severe outcomes among SARI-ICU cases.

                                                   Univariate analysis    Multivariate analysis                          
  -------------------------- --------------------- ---------------------- ----------------------- ---------------------- -------
  RSV                        Negative              ref                                                                   
                             Positive              0 (0)                  1.000                                          
  Adenovirus                 Negative              ref                                                                   
                             Positive              0.294 (0.073-1.176)    0.084                                          
  Rhinovirus                 Negative              ref                                                                   
                             Positive              1.225 (0.053-2.052)    0.899                                          
  Influenza                  Negative              ref                                                                   
                             Positive              3.584 (0.075-11.040)   0.057                                          
  PIV                        Negative              ref                                                                   
                             Positive              1.025 (0.284-3.696)    0.970                                          
  Multiple viruses           Single virus          ref                                            ref                    
                             Multiple viruses      4.362 (1.384-13.754)   0.012                   2.394 (1.009-5.681)    0.055
  Age                        Adults \>18 years     ref                                                                   
                             Children \<18 years   1.749 (0.324-9.428)    0.516                                          
  Gender                     Male                  ref                                                                   
                             Female                0 (0)                  0.999                                          
  Smoking                    No                    ref                                                                   
                             Yes                   2.624 (0.458-15.046)   0.279                                          
  CACI                       ≤3                    ref                                            ref                    
                             \>3                   9.328 (1.860-25.921)   0.020                   7.323 (1.226-23.022)   0.001
  Pneumonia                  None                  ref                                                                   
                             Any                   1.559 (0.313-7.770)    0.588                   ref                    
  Radiologic abnormalities   None                  ref                                            3.339 (1.183-9.422)    0.023
                             Any                   6.332 (1.095-12.645)   0.004                                          
  Respiratory failure        No                    ref                                                                   
                             Yes                   0.937 (0.015-2.243)    0.077                                          
  ARDS                       No                    ref                                                                   
                             Yes                   2.461 (0.075-18.055)   0.613                                          
  Length of hospital stay    None                  ref                    0.025                   ref                    
                             Any                   8.035 (2.005-19.067)                           4.035 (1.011-11.060)   0.005

ICU, intensive care unit; RSV, respiratory syncytial virus, PIV, parainfluenza virus; CACI, Charlson Age-Comorbidity Index; ARDS, acute respiratory distress syndrome; OR, odds ratio.

Finally, the current study has many points of strength; it was the first surveillance that addresses the clinical impacts of viruses causing SARI in the ICU in both children and adult Egyptian population, with enrolled large numbers of patients and over a relatively long period. Moreover, analyses of homogenous populations, rather than different ethnic groups \[[@ref17]\], give the results reliable and strong support. On the other hand, it has some limitations; it reflects an experience of one tertiary care center only, and the flu vaccine was not used.

Conclusions {#sec1-5}
===========

Viral pathogens were encountered in one-third of hospitalized adult and pediatric Egyptian patients with SARI and 20% of them were admitted to the ICU. In comparison to non-ICU patients, SARI-ICU ones had neither significantly predominant clinical signs and symptoms nor radiological features. The presence of chronic respiratory, cardiac, and endocrine disorders negatively affects SARI-ICU patients with influenza. Higher comorbidity index scores, radiological abnormalities, and longer hospital stay are risk factors for severe outcomes in SARI-ICU patients in our locality. Further studies are warranted.
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